Capturing Structured Data in the Electronic Health Record
It is important to realize the full potential of the electronic health record and the impact on oncology care. Challenges persist related to structured data collection at the point of care. There is value in structured data collection for providers, their patients, and healthcare systems in routine clinical care and clinical research.
Category
  • Best Practices
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Cost $0.00
Management of Cancer-Related Fatigue
It is important to learn how to recognize and diagnose cancer-related fatigue so that you can incorporate adequate strategies to manage this distressing symptom to improve the patient’s quality of life.
Category
  • Supportive Care Topics
Format
  • Recorded Webcast
Credits
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
Cost $0.00
NCCN Guidelines® Insights - Colorectal Cancer Screening, Version 1.2024
The NCCN Guidelines for Colorectal Cancer (CRC) Screening describe various colorectal screening modalities as well as recommended screening schedules for patients at average or increased risk of developing sporadic CRC.
Category
  • Colorectal Cancer
Format
  • Monograph/Journal Supplement
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Cost $0.00
Diagnosis and Management of Blastic Plasmacytoid Dendritic Cell Neoplasm
Despite the rarity of blastic plasmacytoid dendritic cell neoplasm (BPDCN), it is crucial for the disease to remain in the differential diagnosis of neoplastic and non-neoplastic skin lesions and rashes, including leukemia cutis, as the disease can disseminate rapidly without therapy.
Category
  • Acute Myelogenous Leukemia
Format
  • Recorded Webcast
Credits
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
Cost $0.00
Evaluation and Treatment of Primary Central Nervous System Lymphoma
Neuroradiologic evaluation, an important part of diagnosis and evaluation of the effectiveness of subsequent therapy, can be confounded by steroids administration used to alleviate symptoms of primary central nervous system lymphomas (PCNSL).
Category
  • CNS Cancers
Format
  • Recorded Webcast
Credits
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
Cost $0.00
Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma
Follicular lymphoma (FL) is characterized by multiple recurrences requiring retreatment. In recent years, EZH2 inhibitors and chimeric antigen receptor (CAR) T-cell therapies have been approved for relapsed/refractory FL after ≥2 prior systemic therapy regimens.
Category
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
Cost $0.00
Management of TP53 Mutated Mantle Cell Lymphoma
Classical mantle cell lymphoma (MCL) with TP53 mutation is associated with inferior survival outcomes to induction chemoimmunotherapy and autologous hematopoietic cell transplant, especially in younger patients.
Category
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
Cost $0.00
Chronic Myeloid Leukemia: How to Treat During Pregnancy
Chronic myeloid leukemia (CML) can affect individuals of reproductive age, and tyrosine kinase inhibitor (TKI) therapy is known to have teratogenic effects. Discontinuing TKI therapy during pregnancy poses a risk of recurrence.
Category
  • Systemic Light Chain Amyloidosis
Format
  • Recorded Webcast
Credits
  • 0.25 AAPA Category 1 CME credit
  • 0.25 ACPE contact hours
  • 0.25 AMA PRA Category 1 Credit™
  • 0.25 ANCC contact hours
  • 0.25 Participation
Cost $0.00
The Role of JAK Inhibitors in the Management of Myelofibrosis
Allogeneic hematopoietic cell transplant is the only potentially curative treatment option resulting in long-term remissions for patients with myelofibrosis (MF), but it is associated with a significant rate of transplant-related complications and morbidity in patients with lower-risk MF.
Category
  • Myeloproliferative Neoplasms
Format
  • Recorded Webcast
Credits
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
Cost $0.00
Amyloidosis: Diagnosis, Treatment, and Supportive Care
High rates of early mortality in newly diagnosed systemic light-chain amyloidosis (SLCA) suggest that there continues to be a delay in early diagnosis.
Category
  • Systemic Light Chain Amyloidosis
Format
  • Recorded Webcast
Credits
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
Cost $0.00

Pages